COVID-19 – Where Does The Pharmaceutical Industry Go From Here?
Shots: The MAA submission to ANVISA is based on P-III APOLLO study results assessing Onpattro in patients hATTR amyloidosis with polyneuropathy, evaluating its safety and efficacy and the results are also published in The New England Journal of Medicine in July 5, 2018 Alnylam’s Onpattro has also received ANIVSA’s Priority Review which is granted to […]Read More
